AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01800643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analyze the pharmacokinetics of busulfan for transplantation
Description: Evaluate the Bu pharmacokinetics (PK) when the drug will be received by P.O or I.V and we will establish the target Area Under Curve- AUC based on a single daily dose (test dose) before HSCT. The test dose of orally Bu is 1 mg/Kg and the blood samples are collected and processed in time: 0h, 30 min, 1h, 1,5h, 2h, 3h, 4h, 5h and 6h after drug intake. After extraction of the plasma samples busulfan, quantitative analyzes of busulfan on human plasma will be performed by the liquid chromatograph. For the patients that will receive intravenously busulfan, the test dose is 32 mg/m2 and blood samples are collected in time: 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after drug intake. The dose during the conditioning will depend on the test dose and the AUC target.
Study NCT04762615 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AMH level measurement
Description: AMH level measurement using ELISA test from blood samples
Study NCT01443221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitiglinide and metformin
Description: Free combination of Mitiglinide 10mg and Metformin 500mg
Study NCT01443221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitiglinide and metformin
Description: Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
Study NCT04590911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enrichment Program (CEP)
Description: Multimodal cognitive rehabilitation program for individuals having sustained a traumatic brain injury during older adulthood
Study NCT02073825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Brief Intervention (WBI)
Description: 4-session WBI
Study NCT02865070 — intervention group
Intervention type: DEVICE
Intervention: Skin Sensor
Description: Wireless vitals monitor
Study NCT01974700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: 500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
Study NCT02907814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: The OCT scan is a brief, non-contact scan of the back of the eye using infrared light. Subjects will see a light and be asked to look forwards while the scan is completed.
Study NCT02907814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Exam
Description: This is a brief, non-contact ocular exam.
Study NCT02624739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reassure Non-Contact Respiration Monitor
Description: Reassure uses a specially-designed, non-contact motion sensor to monitor body movement and continuous respiratory rate (CRR) during sleep. Reassure is used to monitor, over a prolonged period, the sleep patterns and respiration rate while the patient is asleep.
Study NCT02624739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reassure Non-Contact Respiration Monitor
Description: Reassure uses a specially-designed, non-contact motion sensor to monitor body movement and continuous respiratory rate (CRR) during sleep. Reassure is used to monitor, over a prolonged period, the sleep patterns and respiration rate while the patient is asleep.
Study NCT02699879 — intervention group
Intervention type: DRUG
Intervention: Pirfenidone
Description: Pirfenidone will be administered according to the physician discretion as part of standard care.
Study NCT02822625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUTENZA®
Study NCT02822625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QUTENZA®
Study NCT02822625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QUTENZA®
Study NCT02822625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypnotic message
Study NCT02822625 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: music therapy
Study NCT02402088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Imagery
Description: The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as most stressful. Most stressful is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where 1=not at all stressful and 10=the most stress they felt recently in their life. Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work.
Study NCT02402088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Imagery
Description: The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as most stressful. Most stressful is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where 1=not at all stressful and 10=the most stress they felt recently in their life. Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work.
Study NCT02402088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Cue Imagery
Description: A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
Study NCT02402088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Cue Imagery
Description: A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
Study NCT02402088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral-Relaxing
Description: A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
Study NCT02402088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral-Relaxing
Description: A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
Study NCT04186845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPSMA-7.3 (18F) Injection
Description: Radioligand for PET CT scanning
Study NCT01018225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darifenacin
Description: 7.5 or 15 mg darifenacin, once a day for 6 weeks
Study NCT01018225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill, once a day, for six weeks
Study NCT02090634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
Study NCT02090634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
Study NCT02090634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized Texting for Adherence Building (iTAB)
Description: Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
Study NCT01706302 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: The previous study has used four primary data sources: the General Practice Research Data (GPRD \[recently re-named Clinical Practice Research Datalink (CPRD)\], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.
Study NCT03120754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Place the peritoneal drainage
Description: In the experimental group, the abdominal drainage was not placed
Study NCT03120754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No peritoneal drainage
Description: Intraoperative placement of peritoneal drainage as control group.
Study NCT04166825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibrin clot properties
Description: Assessment of thrombin generation and efficiency of fibrinolysis.
Study NCT03266614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery 4 Us
Description: R4US is a social media program aimed at the enhancement of community participation and overall recovery of individuals with psychiatric disabilities.
Study NCT02260076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 400
Study NCT02260076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04236258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIFEdipine ER
Description: Postpartum women with high blood pressure will be randomized to receive nifedipine extended release 30mg daily as their starting antihypertensive.
Study NCT04236258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Postpartum women with high blood pressure will be randomized to receive enalapril 10 mg daily as their starting antihypertensive.
Study NCT03866837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Galacto-oligosaccharides
Description: Galacto-oligosaccharides are classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, are components of cow's milk and have been used repeatedly in clinical trials without adverse effects.
Study NCT03866837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bovine lactoferrin
Description: Bovine lactoferrin is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, is a component of cow's milk and has been used repeatedly in clinical trials without adverse effects.
Study NCT03866837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multiple micronutrient powders with 5 mg iron
Description: The multiple micronutrient powders are composed of Vitamin A, 400 μg; Vitamin D, 5 μg; Tocopherol Equivalents, 5 mg; Thiamine, 0.5 mg; Riboflavin, 0.5 mg; Vitamin B6, 0.5 mg; Folic Acid, 90 μg; Niacin, 6 mg; Vitamin B12, 0.9 μg; Vitamin C, 30 mg; Copper, 0.56 mg; Iodine, 90 μg; Selenium, 17 μg; Zinc, 4.1 mg; Phytase, 190 FTU; Iron, 5 mg \[(as Ferrous fumarate, 2.5 mg and sodium iron ethylenediaminetetraacetate (NaFeEDTA), 2.5 mg\].
Study NCT03866837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multiple micronutrient powders with 5 mg iron
Description: The multiple micronutrient powders are composed of Vitamin A, 400 μg; Vitamin D, 5 μg; Tocopherol Equivalents, 5 mg; Thiamine, 0.5 mg; Riboflavin, 0.5 mg; Vitamin B6, 0.5 mg; Folic Acid, 90 μg; Niacin, 6 mg; Vitamin B12, 0.9 μg; Vitamin C, 30 mg; Copper, 0.56 mg; Iodine, 90 μg; Selenium, 17 μg; Zinc, 4.1 mg; Phytase, 190 FTU; Iron, 5 mg \[(as Ferrous fumarate, 2.5 mg and sodium iron ethylenediaminetetraacetate (NaFeEDTA), 2.5 mg\].
Study NCT03329937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a potent, orally active, highly selective poly adenosine diphosphate (\[ADP\]-ribose) polymerase 1 (PARP1) and PARP2 inhibitor. It will be supplied as 100 mg capsules and will be administered at starting dose of 200 mg PO daily throughout 28 days for 2 cycles (each cycle is 28 days), with the potential for an additional 4 cycles (maximum total of 6 cycles) at the assigned dose and schedule.
Study NCT00449280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg BID (200 mg twice daily)
Study NCT00449280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: 30mg once weekly
Study NCT00449280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: 3mg once daily
Study NCT01747590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Study NCT01747590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Study NCT01747590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study NCT01747590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02427711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar sealer
Description: Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.
Study NCT02427711 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bipolar sealer
Description: Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.
Study NCT06763185 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Supplement: conventional cow's milk consumption, and then A1PF milk consumption
Description: Milk was consumed three times per day after meals, with 250 mL provided at each administration. During washout periods, participants were required to avoid all dairy products and use only rice milk.
Study NCT06763185 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Supplement: A1PF milk consumption, and then conventional cow's milk consumption
Description: Milk was consumed three times per day after meals, with 250 mL provided at each administration. During washout periods, participants were required to avoid all dairy products and use only rice milk.
Study NCT03927261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGN-3006 T Cells
Description: Participants will receive up to 2 intravenous (IV) administrations of PRGN-3006 T Cells with or without lymphodepletion and will be monitored for safety, efficacy, and correlative endpoints for up to 12 months following infusion.
Study NCT02093897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain
Study NCT03265847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-tailored Safety Planning
Description: The intervention will provide safety planning/referrals tailored to the DA
Study NCT03937921 — intervention group
Intervention type: DRUG
Intervention: Gadavist 15Ml Solution for Injection
Description: Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent. The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups. In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.
Study NCT00491985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Inactivated, split-virion pandemic influenza vaccine
Description: 0.5 mL, Intramuscular
Study NCT00491985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Inactivated, split virion pandemic influenza vaccine
Description: 0.5 mL, Intramuscular
Study NCT00491985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Inactivated, split virion pandemic influenza vaccine
Description: 0.25 mL, Intramuscular
Study NCT05877443 — intervention group
Intervention type: PROCEDURE
Intervention: Open system
Description: Oxygen delivered on open system, for example high flow nasal cannula or low flow oxygen by nasal cannula or face mask
Study NCT05877443 — intervention group
Intervention type: PROCEDURE
Intervention: Non-invasive mechanical ventilation
Description: Respiratory support by for example continues or bilevel positive airway pressure
Study NCT05877443 — intervention group
Intervention type: PROCEDURE
Intervention: Invasive mechanical ventilation
Description: Respiratory support delivered through endotracheal tube or tracheostomy
Study NCT01641263 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education Therapy
Description: Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
Study NCT01641263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitve Behavioral Therapy for Insomnia
Description: For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
Study NCT02178059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbutaline sulphate delivered dose
Description: 0.4 mg terbutaline sulphate (delivered dose) per inhalation
Study NCT02178059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terbutaline sulphate metered dose
Description: 0.5 mg terbutaline sulphate (metered dose) per inhalation
Study NCT02198495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation of ferric carboxymaltose
Study NCT02198495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation of iron sucrose
Study NCT00437645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160 mg capsules
Study NCT00437645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg capsules
Study NCT00437645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 mg capsules
Study NCT00437645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg capsules
Study NCT00437645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: capsules
Study NCT00437645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: capsules
Study NCT02782390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental Restoration with Stainless Crown
Description: Lesions allocated to this group will be treated with stainless dental crowns according to the Hall Technique protocol (Evans \& Innes, 2010).
Study NCT02782390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental Restoration with Composite Resin
Description: Surfaces allocated to this group will be treated with composite resin (Z250, 3M ESPE, USA) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 15 seconds, followed by spray of water/air for at least 15 seconds. Then, the adhesive system (Single Bond, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions. Finally, composite resin (Z250, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions.
Study NCT00605202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25 mg a day for 14 days.
Study NCT00605202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Licorice
Description: Licorice candy 32 grams a day for 14 days.
Study NCT03586583 — intervention group
Intervention type: DEVICE
Intervention: FBP
Description: Old processing
Study NCT03586583 — intervention group
Intervention type: DEVICE
Intervention: ISR
Description: New processing
Study NCT01756664 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Study NCT01756664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Study NCT00823784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal doppler hemorrhoidal ligation
Description: THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy
Study NCT00823784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stapled hemorrhoidopexy
Description: Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture
Study NCT00961298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.